MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.155
-0.045
-3.75%
Opening 11:12 07/01 EDT
OPEN
1.190
PREV CLOSE
1.200
HIGH
1.190
LOW
1.150
VOLUME
144.46K
TURNOVER
111.69K
52 WEEK HIGH
3.660
52 WEEK LOW
0.7954
MARKET CAP
114.08M
P/E (TTM)
-0.7320
1D
5D
1M
3M
1Y
5Y
Adverum Biotech Receives EMA's Priority Medicines Status For Chronic Eye Disorder Candidate
The European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ (NASDAQ: ADVM)  lead drug ADVM-022 for the treatment of wet age-related macular degeneration (wet AMD).
Benzinga · 06/24 15:09
BRIEF-Adverum Receives Priority Medicines Designation By EMA For ADVM-022 In Wet AMD
reuters.com · 06/24 12:35
Adverum Biotechnologies Granted Priority Medicines Designation By European Medicines Agency For ADVM-022 In Wet AMD
Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) has granted ADVM-022
Benzinga · 06/24 12:04
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
REDWOOD CITY, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) ...
GlobeNewswire · 06/24 12:00
Short Volatility Alert: Adverum Biotechnologies, Inc.
On Tuesday, shares of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) experienced volatile short activity. After the activity, the stock price went down -2.74% to $0.9259.  The overall sentiment for ADVM has been Bearish.
Benzinga · 06/15 14:46
Adverum wet AMD candidate ADVM-022 shows long-term benefit after single injection
A single injection of Adverum Biotechnologies' (NASDAQ:ADVM) ADVM-022 for wet AMD demonstrated therapeutic aflibercept expression levels over three years and was well tolerated. Results also showed that ADVM-022 led to
Seekingalpha · 06/09 14:47
BRIEF-Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression After Single Ivt Injection Of Advm-022
reuters.com · 06/09 12:15
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
- Three-year aflibercept protein expression demonstrates continuous and consistent therapeutic levels from ADVM-022 in OPTIC study subjects with wet age-related macular degeneration (wet AMD) - New data highlight ADVM-022 reductions in mean annualized anti...
GlobeNewswire · 06/09 12:00
More
No Data
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
25.00%Buy
75.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADVM stock price target is 4.000 with a high estimate of 6.00 and a low estimate of 3.000.
High6.00
Average4.000
Low3.000
Current 1.180
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 150
Institutional Holdings: 74.53M
% Owned: 75.46%
Shares Outstanding: 98.77M
TypeInstitutionsShares
Increased
13
12.68M
New
9
418.81K
Decreased
40
13.58M
Sold Out
16
1.85M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Machado
President/Chief Executive Officer/Director
Laurent Fischer
Chief Financial Officer
John Rakow
Chief Operating Officer
Kishor Soparkar
Chief Scientific Officer
Brigit Riley
Other
Richard Beckman
Other
Setareh Seyedkazemi
Independent Director
Soo Hong
Independent Director
Mark Lupher
Independent Director
Rabia Ozden
Independent Director
James Scopa
Independent Director
Dawn Svoronos
Independent Director
Reed Tuckson
Independent Director
Scott Whitcup
No Data
No Data
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company, which targets unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates. Its lead product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. The Company's second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.